Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes.

about

Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes.

Item

http://www.wikidata.org/entity/Q49838232

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Discovery of an Isothiazole-Ba ...... Candidate for Type 2 Diabetes.

@en

Discovery of an Isothiazole-Ba ...... Candidate for Type 2 Diabetes.

@nl

type

Item

label

Discovery of an Isothiazole-Ba ...... Candidate for Type 2 Diabetes.

@en

Discovery of an Isothiazole-Ba ...... Candidate for Type 2 Diabetes.

@nl

prefLabel

Discovery of an Isothiazole-Ba ...... Candidate for Type 2 Diabetes.

@en

Discovery of an Isothiazole-Ba ...... Candidate for Type 2 Diabetes.

@nl

P1476

Discovery of an Isothiazole-Ba ...... Candidate for Type 2 Diabetes.

@en

P2093

Arthur Suckow

http://www.w3.org/2001/XMLSchema#string

Austin Bell

http://www.w3.org/2001/XMLSchema#string

Celia Jenkinson

http://www.w3.org/2001/XMLSchema#string

Chaozhong Cai

http://www.w3.org/2001/XMLSchema#string

Hong Hua

http://www.w3.org/2001/XMLSchema#string

James Leonard

http://www.w3.org/2001/XMLSchema#string

Joseph Gunnet

http://www.w3.org/2001/XMLSchema#string

Mark Macielag

http://www.w3.org/2001/XMLSchema#string

Peter Haug

http://www.w3.org/2001/XMLSchema#string

Wen Yan

http://www.w3.org/2001/XMLSchema#string

P2860

GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects

Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120

Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human

Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion.

Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review.

Free fatty acid receptors: emerging targets for treatment of diabetes and its complications.

The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism

Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity.

Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).

A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice.

P304

947-952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSMEDCHEMLETT.7B00233

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28947942

http://www.w3.org/2001/XMLSchema#string

P932

5601374

http://www.w3.org/2001/XMLSchema#string